Halozyme Therapeutics Inc
$ 66.64
-2.07%
16 Apr - close price
- Market Cap 8,062,177,000 USD
- Current Price $ 66.64
- High / Low $ 68.84 / 66.36
- Stock P/E 26.58
- Book Value 0.41
- EPS 2.56
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.22 %
- ROE 1.54 %
- 52 Week High 82.22
- 52 Week Low 47.50
About
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Analyst Target Price
$84.89
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.49 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HALO
2026-04-15 17:08:49
Halozyme Therapeutics (HALO) is projected to announce a year-over-year increase in both earnings and revenues for the quarter ending December 2025. The company is expected to post quarterly earnings of $2.15 per share, up 70.6%, and revenues of $448.62 million, a 50.5% increase. However, with a 0% Earnings ESP and a Zacks Rank #3, it is difficult to conclusively predict an earnings beat.
2026-04-14 10:09:41
The article focuses on the working capital per share for Halozyme Therapeutics, Inc. (BX:RV7), a biotechnology company listed on BX Swiss. It presents a financial overview of the company, highlighting its stock information and basic financial metrics within the TradingView platform context. The main content indicates the availability of working capital per share data for various periods, emphasizing its relevance to investors and financial analysts.
2026-04-13 17:08:49
Paragon Capital Management Inc. initiated a new position in Halozyme Therapeutics (NASDAQ:HALO) by purchasing 18,920 shares valued at approximately $1.27 million in Q4. This move comes as institutional investors now hold 97.79% of the company's stock, despite recent insider selling by top executives. Halozyme reported a significant EPS miss but strong revenue growth, with analysts currently holding a "Hold" rating and a target price of $78.56.
2026-04-13 13:40:29
TD Cowen has reiterated a Buy rating and a $96.00 price target for Halozyme Therapeutics (NASDAQ:HALO), citing strong royalty growth drivers from products like Vyvgart Hytrulo, Darzalex Faspro, and Phesgo. The firm believes Halozyme is undervalued and expects continued outperformance, highlighting impressive 37.6% revenue growth and anticipated net income growth. Recent developments, including a collaboration with Vertex Pharmaceuticals and an FDA approval for a combination therapy leveraging Halozyme's technology, further support the positive outlook.
2026-04-13 10:52:00
Paragon Capital Management Inc. has significantly increased its stake in Halozyme Therapeutics (NASDAQ:HALO) by purchasing 18,920 shares in Q4, valued at approximately $1.27 million. This investment highlights Paragon Capital's confidence in the biotech firm's growth potential and its innovative drug delivery technologies, particularly its ENHANZE platform. The move underscores the appeal of Halozyme among institutional investors in the pharmaceutical sector.
2026-04-13 10:40:29
Halozyme Therapeutics recently announced a collaboration and licensing deal with Vertex Pharmaceuticals for its Hypercon technology, including a US$15 million upfront payment. While the stock has seen renewed momentum, trading at US$67.82 against an analyst target of US$84.89, different valuation signals present a mixed picture. The company's ENHANZE platform benefits from the shift to subcutaneous drug delivery, suggesting an undervalued long-term future, but its P/E ratio, higher than peers, indicates potential valuation risk.
